Drug Trial Radar · NCT04432454
Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Last checked: Nov 19, 2026Latest source record: Feb 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
29
Actual
Start
Sep 29, 2020
Primary completion
Jan 28, 2025
Study completion Jan 28, 2025
Sponsor
- Lead sponsor
- Sermonix Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 16, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicenter, single-arm safety study evaluating the safety and tolerability of the lasofoxifene and abemaciclib combination for the treatment of pre- and postmenopausal women with locally advanced or metastatic ER+/HER2- breast cancer who have disease progression on first and/or 2nd lines of hormonal treatment for metastatic disease and have an ESR1 mutation.
Conditions
- Metastatic Breast Cancer
Interventions
Lasofoxifene and abemaciclib (VERZENIO (R)).Drug
Lasofoxifene 5 mg given once a day orally and abemaciclib 150 mg given twice a day orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of the combination of lasofoxifene and abemaciclib as measured by number of adverse events (AEs), severity of AEs and mortality due to AEs at every scheduled visit.Time frame: All subjects enrolled in the study will be treated until documented disease progression or until withdrawal for any reason. Safety and tolerability will be assessed from enrollment up to 24 months.
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham (UAB) - Comprehensive Cancer Center
Birmingham, Alabama
Yuma Regional Medical Center
Yuma, Arizona
Compassionate Cancer Care Med Group - Clinic Aid USA - Fountain Valley
Fountain Valley, California
St. Joseph Health
Santa Rosa, California
Mayo Jacksonville
Jacksonville, Florida
Illinois Cancer Care
Peoria, Illinois
Beacon Health System Memorial Regional Cancer Center
South Bend, Indiana
Mayo Clinic Rochester
Rochester, Minnesota
New Jersey Cancer Care, PA
Belleville, New Jersey
Cleveland Clinic
Cleveland, Ohio
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio
Mary Crowley Cancer Research
Dallas, Texas
MD Anderson Cancer Center
Houston, Texas
Oncology Consultants, P.A.
Houston, Texas
Hematology Oncology Associates of Fredericksburg
Fredericksburg, Virginia
Northwest Medical Specialists, PLLC (NWMS)
Tacoma, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.